Literature DB >> 21245676

Organized colorectal cancer screening programmes: how to optimize efficiency in the general population.

Anne Calazel-Benque1, Jérôme Viguier, Claire Roussel, Xavier Pivot, François Eisinger, Jean-Yves Blay, Yvan Coscas, Jean-François Morère.   

Abstract

In France, free faecal occult blood testing is offered to individuals aged between 50 and 74 years every 2 years as a method of screening for colorectal cancer (CRC). To assess how a proposed organized programme of CRC screening would be perceived among a representative sample of individuals living in France, aged between 40 and 75 years, and by a representative sample of general practitioners, two nationwide observational telephone surveys were carried out in 2005 (EDIFICE 1; 1601 individuals) and 2008 (EDIFICE 2; 1801 individuals). In 2008, 38% of individuals aged between 50 and 74 years reported undergoing screening for CRC; this corresponded to a statistically significant 13% increase in CRC screening rate compared with 2005 (P=0.01). When asked whether it was possible to screen for CRC, 94% of individuals who had undergone screening (N=350) responded positively compared with 87% of individuals who had not been screened. The main reason for individuals not to undergo screening was a lack of awareness (35% of men and 37% of women, P=not significant); the second reason was lack of advice and referral from their general practitioner (21% of women versus 15% of men, P=0.03). The French population is aware of the potential benefit of CRC screening; however, many do not undergo regular screening. It is therefore important to identify the hurdles associated with CRC screening.

Entities:  

Mesh:

Year:  2011        PMID: 21245676     DOI: 10.1097/01.cej.0000391566.41383.61

Source DB:  PubMed          Journal:  Eur J Cancer Prev        ISSN: 0959-8278            Impact factor:   2.497


  1 in total

1.  Recruiting patients into the CDC's Colorectal Cancer Screening Demonstration Program: strategies and challenges across 5 sites.

Authors:  Jennifer E Boehm; Elizabeth A Rohan; Judith Preissle; Amy DeGroff; Rebecca Glover-Kudon
Journal:  Cancer       Date:  2013-08-01       Impact factor: 6.860

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.